The agents reducing ezrin expression may overcome resistance to PD-1/PD-L1 blockade treatments and may also be a possible adjuvant therapies for the current ICB Abs, possibly by modulating PD-L1 protein expression in human cervical cancers. This evidence concerns the gene PDCD1 and cervical cancer.